Manuscripts and Presentations

Most Recent

H. Heussler, J. Cohen, N. Silove, N. Tich, M. Bonn-Miller, W. Du, C. O’Neill, and T. Sebree. A Phase 1/2, Open-Label Assessment of the Safety, Tolerability, and Efficacy of Transdermal Cannabidiol (ZYN002) for the Treatment of Pediatric Fragile X Syndrome. Journal of Neurodevelopmental Disorders 2019; 11:16.
Journal Article PDF

Zygel™ (ZYN002 CBD Gel)

H. Heussler, J. Cohen, N. Silove, N. Tich, T. Sebree, S. Siegel, and D. Gutterman. Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS). 2019 Annual Meeting of the American Psychiatric Association. San Francisco, CA. May 18-22, 2019.
Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome

H. Heussler, J. Cohen, N. Silove, N. Tich, T. Sebree, and S. Siegel. Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS). 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP). Hollywood, FL. December 9-12, 2018.
Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome

T. O’Brien, MD, FRACP; S. Berkovic, MD, FRACP; J. French; J. Messenheimer, MD; M. Bonn-Miller, PhD; and D. Gutterman, PharmD. Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults. American Epilepsy Society Annual Meeting 2018. New Orleans, LA. November 29-Dec. 4, 2018.
Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults

Gonzalez-Cuevas G, et alUnique treatment potential of cannabidiol for the prevention of relapse to drug use: Preclinical proof of principal. Neuropsychopharmacology DOI: 10.1038/S41386-018-0050-8.
Please see the Springer Nature press release here.
CBD for prevention of relapse to drugs

H. Heussler, J. Cohen, N. Silove, N. Tich, T. Sebree, and S. Siegel. Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS). 16th NFXF (National Fragile X Foundation) International Fragile X Conference. Cincinatti, OH. July 12, 2018.
Presentation
Poster

O’Brien T MD, FRACP; Berkovic, S, MD, FRACP; French, J, MD, et al. Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults. 2017 American Epilepsy Society Annual Meeting, Washington, DC. December 1-5, 2017.
Synthetic Transdermal CBD in Adult Focal Epilepsy

Bonn-Miller M, Gutterman D. A Permeation-Enhanced Synthetic Cannabidiol (CBD) Transdermal Gel for the Treatment of PTSD. Military Health System Research Symposium. Orlando, FL. August 15-18, 2016.
CBD Gel for PTSD

Bonn-Miller M, Sebree T, O’Neill C, Messenheimer J. Neuropsychological Effects of ZYN002 (Synthetic Cannabidiol) Transdermal Gel in Healthy Subjects and Patients with Epilepsy: Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies. American Epilepsy Society Annual Meeting. Houston, TX. December 2-6, 2016.
Neuropsychological Effects of ZYN002

Sebree T, O’Neill C, Messenheimer J, Gutterman D. Safety and Tolerability of ZYN002 (Synthetic Cannabidiol) Transdermal Permeation-Enhanced Gel in Healthy Subjects and Epilepsy Patients: Three Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies. American Epilepsy Society Annual Meeting. Houston, TX. December 2-6, 2016.
ZYN002 Safety and Tolerability

Cannabinoids and  Delivery Systems

R. Mannion. Cannabinoid Manufacturing & Product Quality. U.S. Food and Drug Administration’s Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds Public Hearing.  Silver Spring, MD. May 31, 2019.
Zynerba presentation from FDA’s Cannabis or Cannabis-Derived Compounds public hearing

Merrick J, Lane B, Sebree T, Yaksh T, O’Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis and Cannabinoid Research 2016;1:1, 102–112, DOI: 10.1089/can.2015.0004.
Link to Article

Bonn-Miller M, Banks SL,  Sebree T. Conversion of Cannabidiol Following Oral Administration: Authors’ Response to Grotenhermen et al. Cannabis and Cannabinoid Research 2017;2:1, 5-7.
Link to Article

Paudel KS, Hammell DC, et al. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancersDrug Development and Industrial Pharmacy 2010;36(9):1088–1097.
Link to Article

Fragile X Syndrome

Jung KM, Sepers M, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012;3:1080.
Link to Article

Qin M, Zeidler Z, et al. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome. Behav Brain Res 2015 Sep 15;291:164-71.
Link to Article

Epilepsy

Consroe P, Wolkin A. Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther. 1977 Apr;201(1):26-32.
Link to Article

Consroe P, Benedito MA, et al. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol. 1982 Sep 24;83(3-4):293-8.
Link to Article

Cunha JM, Carlini EA, et al. Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients. Pharmacology 1980;21:175-185.
Link to Article

Devinsky O, Marsh E, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15: 270–78.
Link to article

Friedman D and Devinsky O. Cannabinoids in the Treatment of Epilepsy. N Engl J Med 2015; 373:1048-1058.
Link to Article

Jones NA, Glyn SE, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012 Jun;21(5):344-52.
Link to Article

Jones NA, Hill AJ, Smith I, et al. Cannabidiol Display Antiepileptiform and Antiseizure Properties In Vitro and In Vivo. J Pharmac. and Exper. Therap. 2010;332(2):569-577.
Link to Article

Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsyEpilepsy & Behavior 2013;29:574–577.
Link to Article

Autism Spectrum Disorder

Poleg S, Golubchik P, Offen D, Weizman A. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:90-96.
Link to Article

Baumer N, Spence SJ. Evaluation and Management of the Child With Autism Spectrum Disorder. Continuum. 2018;24:248-275.
Link to Article

Wei D, Allsop S, Tye K, Piomelli D. Endocannabinoid Signaling in the Control of Social Behavior. Trends Neurosci. 2017;40(7):385-396.
Link to Article

22q11.2 Deletion Syndrome

McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, Zackai EH, Emanuel BS, Vermeesch JR, Morrow BE, Scambler PJ, Bassett AS. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071.
Link to Article

Swillen A, McDonald-McGinn D. Developmental trajectories in 22q11.2 deletion. Am J Med Genet C Semin Med Genet. 2015;169(2):172-81.
Link to Article